Alterations of PTEN were reported in breast, multiple myeloma, and endometrial cancers, and treatment with mTOR inhibitors displayed strong antitumor activity in these cancers.96–98 Inactivation of TSC1/2 has been observed in tuberous sclerosis and can initiate tumorigenesis. Here, MTOR is linked to plasma cell myeloma.